Granulocyte colony-stimulating factor - Shire Pharmaceuticals

Drug Profile

Granulocyte colony-stimulating factor - Shire Pharmaceuticals

Alternative Names: G-CSF - Shire Pharmaceuticals; G-CSF - Transkaryotic Therapies; Gene-activated G-CSF; Gene-activated granulocyte colony-stimulating factor

Latest Information Update: 02 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Neutropenia

Most Recent Events

  • 02 May 2007 No development reported - Phase-I for Neutropenia in USA (Injection)
  • 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
  • 23 Aug 2004 This compound is available for licensing (http://www.transkaryotictherapies.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top